Regentis Biomaterials (RGNT) Equity Ratio (2024 - 2025)

Regentis Biomaterials (RGNT) reported Equity Ratio of 0.62 for Q4 2025, up 100.73% year-over-year from 0.31 in Q4 2024, and up 100.73% quarter-over-quarter from 85.28 in Q4 2024.

Regentis Biomaterials (RGNT) Equity Ratio (2024 - 2025) Analysis & Trends

Regentis Biomaterials (RGNT) has 2 years of Equity Ratio data on file, last reported at 0.62 in Q4 2025.

  • Equity Ratio for Q4 2025 came in at 0.62, up 100.73% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.62 (up 100.73% YoY), and the FY2025 annual result was 0.62, up 100.73% from the prior year.
  • Equity Ratio grew to 0.62 in Q4 2025 per RGNT's latest filing, from 85.28 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.62 in Q4 2025 and troughed at 85.28 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Intuitive Surgical 148.09 Bn 143.69 Bn 1.83 Bn 0.88
2 Becton Dickinson 41.00 Bn 39.99 Bn 2.15 Bn 0.47
3 Medline 30.38 Bn 36.22 Bn 1.84 Bn 0.29
4 Resmed 28.22 Bn 26.56 Bn 890.98 Mn 0.74
5 West Pharmaceutical Services 23.72 Bn 23.19 Bn 296.40 Mn 0.73
6 Solventum 13.33 Bn 13.33 Bn 1.10 Bn 0.35
7 Cooper Companies 13.12 Bn 12.99 Bn 735.40 Mn 0.66
8 Align Technology 12.86 Bn 11.80 Bn 736.59 Mn 0.66
9 Baxter International 10.51 Bn 8.47 Bn 891.00 Mn 0.30
10 Regentis Biomaterials 3.72 Mn -3.66 Mn - 0.62

Historic Data

Download Data
DateValue
Dec 31, 2025 0.62
Dec 31, 2024 -85.28